2.90Open2.90Pre Close0 Volume229 Open Interest15.00Strike Price0.00Turnover149.49%IV0.96%PremiumJan 17, 2025Expiry Date2.73Intrinsic Value100Multiplier6DDays to Expiry0.17Extrinsic Value100Contract SizeAmericanOptions Type0.8274Delta0.0725Gamma5.72Leverage Ratio-0.0718Theta0.0020Rho4.73Eff Leverage0.0060Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet